ST2 assay (Soluble suppression of tumorigenicity 2)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ST2 assay (Soluble suppression of tumorigenicity 2), covering 2018-08-20 to 2018-08-20. Get the full timeline:
Most recent: Clinical Trial Update: Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). [Phase 4]